Smoking and Vaping in Recovery: Why Tobacco Belongs in Addiction Treatment

There is a moment most families recognize. The person comes home from detox or residential treatment, the discharge papers list a follow-up appointment and a therapy schedule, and then, somewhere in the first week, someone offers a cigarette — and the whole room relaxes. Nobody objects. Quitting alcohol or opioids was the point. Smoking, everyone quietly agrees, can wait.

That agreement is one of the most consequential unwritten rules in addiction care, and it is wrong. Tobacco is not a harmless companion to recovery. In a long-term study of people treated for alcoholism and other drug dependence, tobacco caused more of their deaths than the drug that brought them into treatment. For families trying to keep someone alive, it belongs on the same page as everything else.

This guide is about what the evidence actually says: how common tobacco dependence is among people in treatment, why programs spent decades avoiding it, what happens to mood and sobriety when someone quits, what the 2026 nicotine market looks like, which treatments work, and what a family can do without starting a fight.

The number that changes the conversation

In 1996, researchers at the Mayo Clinic followed 845 people admitted to an inpatient addiction program in Olmsted County, Minnesota, for an average of more than ten years. Seventy-eight percent were treated for alcohol dependence alone, 18 percent for alcohol plus another drug, and 4 percent for a non-alcohol drug. At admission, 75 percent were current cigarette smokers.

By the end of follow-up, 222 of them had died. Death certificates were obtained for 214. When the underlying cause of death was classified using CDC categories, 50.9 percent were tobacco-related and 34.1 percent were alcohol-related. Overall mortality was far above what would be expected for people of the same age, sex, and birth year: at 20 years, 48.1 percent had died versus an expected 18.5 percent.

The authors' conclusion was blunt for 1996 and remains uncomfortable now: these patients' excess mortality "was due more to tobacco-related than to alcohol-related causes," and nicotine dependence treatment in this population is "imperative."

Nothing about that arithmetic has changed. What has changed is that treatment programs are now largely smoke-free indoors, which means the cigarette moved to the parking lot, the back porch, and the recovery meeting that lets out into a huddle of smokers.

How common is tobacco dependence in this population?

The Cochrane review cited below puts smoking rates among people with alcohol and other drug dependence at two to four times those of the general population. The Mayo cohort found three out of four patients smoking at admission.

That is not a coincidence of culture. Nicotine works on the same reward circuitry as every other addictive drug: it triggers the release of dopamine and, through the adrenal glands, epinephrine, raising heart rate and blood pressure. The NIDA fact sheet on vaping devices describes nicotine as activating the brain's reward circuits in a way that "motivates some people to use nicotine again and again, despite risks to their health and well-being." The mechanism is not milder because the delivery is legal.

For families, this produces a specific and confusing grief: the person did the hard thing, completed treatment, and is still using a substance daily — one that is sold at every gas station on the drive home.

"Don't quit everything at once" — where that advice came from

Ask a counselor why the program does not address cigarettes and you will usually hear some version of: it is too much at once, and if we push tobacco we might destabilize the sobriety that matters.

That concern was not invented out of laziness. It was the clinical default for decades, and it rested on an assumption that had never been tested properly. Then it was tested.

A Cochrane systematic review published in 2016 pooled 35 randomized controlled trials with 5,796 participants — people in treatment for, or in recovery from, alcohol and other drug dependence. The trials tested counseling, medication, or both, against usual care. The findings:

• Pharmacotherapy increased tobacco abstinence: risk ratio 1.60 (95% CI 1.22 to 2.12).
• Counseling plus pharmacotherapy increased tobacco abstinence: risk ratio 1.74 (95% CI 1.39 to 2.18).
• Counseling alone did not significantly increase abstinence: risk ratio 1.33 (95% CI 0.90 to 1.95).
• The effect held for people in treatment (1.99) and in recovery (1.33), for alcohol dependence (1.47) and for other drug dependence (1.85).

And the number that matters most to the original objection: there was no difference in abstinence from alcohol and other drugs between people who got tobacco treatment and people who did not — risk ratio 0.97 (95% CI 0.91 to 1.03).

In plain language: treating tobacco did not cost anyone their sobriety. The review's authors noted the evidence quality was low to moderate, mainly because the trials reported their methods poorly, but the direction was consistent across settings and substances. Their recommendation was that tobacco cessation treatment "should be incorporated into clinical practice" for this population.

The fear was reasonable. The evidence does not support it.

What quitting does to mood

The second objection families raise is mood: this person is already anxious and depressed, and taking away cigarettes will make it worse. It is a fair worry — nicotine withdrawal genuinely includes irritability, low mood, and poor concentration in the short run, much like the first weeks described in our guide to detox and withdrawal management.

The longer run points the other way. A 2014 BMJ systematic review and meta-analysis pooled 26 longitudinal studies that measured mental health before quitting and at least six weeks after. Compared with people who kept smoking, those who quit showed significant improvements in:

• anxiety (standardized mean difference −0.37)
• depression (−0.25)
• mixed anxiety and depression (−0.31)
• stress (−0.27)
• psychological quality of life (+0.22)
• positive affect (+0.40)

Critically, the authors found no evidence that the effect size differed between the general population and populations with physical or psychiatric disorders — and concluded the effect sizes were "equal or larger than those of antidepressant treatment for mood and anxiety disorders."

This is one of the few places in addiction care where the honest answer is better than the reassuring myth. Quitting does not trade sobriety for depression. On average, mood improves.

The 2026 nicotine market: vapes, pouches, and "tobacco-free" nicotine

Twenty years ago the family conversation was about cigarettes. Today the same person may be using a disposable vape in the car, a nicotine pouch at work, or a product marketed as "tobacco-free" — and each of those needs to be part of the same conversation.

Vapes. NIDA describes vaping devices as battery-operated products that deliver an aerosol typically containing nicotine plus flavorings and other chemicals, and notes that vaping is now the most commonly used form of nicotine among youth in the United States. Some research suggests vaping may be less harmful than combustible cigarettes when a person who smokes switches to it completely — but that is a statement about relative risk in adults who already smoke, not a statement of safety.

Nicotine pouches. CDC reviewed this product class in January 2025. The pouches hold a nicotine powder that dissolves against the gum, require no spitting, and come in flavors such as cinnamon, citrus, mint, and coffee. Sales grew from 126 million pouches in August 2019 to 808 million in March 2022, with the fastest growth in higher-strength products. In 2022, 2.9 percent of U.S. adults had ever used them and 0.4 percent used them currently; in 2024, 1.8 percent of middle and high school students reported current use. Some contain laboratory-made nicotine and are sold as "tobacco-free" — CDC notes there is little chemical difference between tobacco-derived and synthetic nicotine.

The line that matters for recovery: the FDA has not approved nicotine pouches, or e-cigarettes, as smoking cessation aids. They are nicotine delivery products, not treatment. Using one to stop smoking is not the same as being treated for tobacco dependence, and for adolescents and pregnant women CDC is explicit that these products should not be used at all.

One more consideration specific to recovery: NIDA notes that nicotine can prime the brain's reward system, which may put users at risk for addiction to other drugs. For someone rebuilding a life around sobriety, that is an argument for treating nicotine seriously, not for ignoring it.

What actually works

The clinical picture is unusually clear. CDC describes tobacco use and dependence as "a chronic, relapsing condition that often requires repeated intervention and long-term support" — the same framing used for any other substance use disorder — and lists what works.

Counseling

Behavioral support can be delivered in person, one-on-one or in a group, and by telephone through a state quitline. Text-messaging programs and web-based programs also help. Brief advice counts: CDC reports that even advice lasting less than three minutes from a health professional improves the chance of quitting successfully and is highly cost-effective.

Medication

Seven medications are FDA-approved for smoking cessation. They fall into three groups:

• Nicotine replacement therapy (NRT) reduces withdrawal symptoms. The patch, gum, and lozenge are available over the counter; the inhaler and nasal spray are prescription.
• Varenicline is a prescription nicotine receptor partial agonist. It reduces craving and withdrawal and blocks the rewarding effects of cigarettes.
• Bupropion is a prescription antidepressant with nicotinic antagonist properties that reduces craving and withdrawal.

Two combination facts are worth knowing before you talk to a prescriber. First, using counseling and medication together can more than double the chance of quitting compared with either alone. Second, combining a long-acting NRT (the patch) with a short-acting form (gum or lozenge) increases the chances beyond a single product.

The gap between what works and what people get

CDC's 2022 survey data show how far short of that standard routine care falls:

• 67.7 percent of adults who smoked said they wanted to quit.
• 53.3 percent had tried to quit in the past year.
• 8.8 percent succeeded.
• Among those who saw a health professional during the year, 50.5 percent received advice to quit and 49.2 percent received assistance.
• Among those who tried to quit, 38.3 percent used counseling or medication, and only 5.3 percent used both.

That 5.3 percent is the number to hold onto. The treatment exists, it is cheap relative to everything else in addiction care, and almost nobody gets the full version.

What to ask the treatment program

If your family member is currently in treatment, these questions will tell you in five minutes whether tobacco is being treated or merely tolerated:

• Is tobacco treatment part of the program, or only a smoke-free policy? A policy without treatment produces withdrawal in the parking lot.
• Do you offer NRT on site, including for someone who did not ask for it?
• Will you prescribe or refer for varenicline or bupropion if NRT is not enough?
• Is quitting tobacco part of the discharge plan, alongside the therapy and medication schedule?
• Does the program coordinate with the prescriber who manages any psychiatric medication, including in co-occurring disorder care?
• For pregnant patients: is the plan behavioral-first, as CDC recommends, with medication decisions made case by case? Our guide to treatment during pregnancy walks through what to ask.

If the answer is "we don't do tobacco," that is not a reason to leave a program that is otherwise good. It is a reason to raise it, and to make sure the primary care visit after discharge is booked with someone who will.

What families can do — and what backfires

What helps:

• Say it once, plainly, and connect it to love rather than disappointment. "I want you alive in twenty years" lands differently than "you traded one addiction for another."
• Treat it as a medical problem with a treatment. Offer to help find a prescriber, or to call the quitline together.
• Timing matters. The first weeks after discharge are overloaded. If the person is fighting to stay off opioids, ask whether they would be willing to address tobacco at the 60- or 90-day mark, and write the date down.
• Make the house easier. Remove ashtrays, know that a smoke-free home is not the same as a judgment, and keep NRT where the person can actually reach it — the same logic as the rest of a recovery-friendly home.
• Expect several attempts. CDC is explicit that quitting often requires multiple tries; a relapse to smoking is not a failure of the recovery, it is the normal shape of this condition. Expect a few rough nights of sleep too — our guide to sleep in early recovery covers what helps, and how to fold a quit attempt into a relapse prevention plan without letting one slip define the whole thing.
• Protect your own exposure. Secondhand smoke and vaping aerosol affect everyone in the house, including children.

What backfires:

• Ultimatums. Threatening to withdraw support over cigarettes usually breaks the relationship without changing the behavior.
• Using tobacco as proof of dishonesty. Sneaking cigarettes is not evidence that the person is using again.
• Weaponizing it during an argument about something else.
• Nagging a person who is in acute withdrawal from their primary substance. In that window, survival comes first; the tobacco conversation can wait two weeks without becoming an abandonment of it.
• Assuming a vape or a pouch is "harmless" and therefore not worth mentioning to the prescriber.

Where to get help

• 988 Suicide and Crisis Lifeline — call or text 988 for mental health crisis, including dangerous withdrawal or suicidal thoughts.
• SAMHSA National Helpline — 1-800-662-4357 — free, confidential, 24/7 treatment referral for substance use and mental health.
• 1-800-QUIT-NOW (1-800-784-8669) — the national telephone quitline portal, which routes to your state's service.
• cdc.gov/quit and smokefree.gov — free text-messaging and web-based quitting programs.
• FindTreatment.gov — treatment locator for programs that address co-occurring conditions.

The bottom line

Tobacco is not a side issue in recovery. In the only long-term cohort that has measured this carefully, it killed more people after addiction treatment than alcohol did, and the treatments that work are FDA-approved, widely available, and used by fewer than one in twenty people who try to quit.

The advice to "not quit everything at once" was well-intentioned and, as it turns out, wrong: the best evidence we have shows that treating tobacco does not reduce abstinence from alcohol or other drugs. Meanwhile, quitting tends to improve mood rather than damage it.

If someone you love is in recovery and still smoking, vaping, or using pouches, the useful question is not whether they should quit. It is who is going to prescribe the medication, when the follow-up is booked, and whether the program you are paying for is willing to treat the addiction that is most likely to kill them.